PARP 억제제 바이오마커 시장 : 제품, 서비스, 용도, 최종 용도별, 세계 예측(2024-2032년)

Global PARP Inhibitor Biomarkers Market will record over 8.3% CAGR from 2024 to 2032, ushered by ongoing research and development efforts focused on broadening the application of PARP inhibitors. This continuous exploration aims to uncover new therapeutic avenues beyond existing uses, enhancing treatment options for diverse patient populations. These drug development initiatives are pivotal in advancing precision medicine and tailoring treatments based on specific genetic profiles and biomarkers. Such endeavors usher innovation and contribute to expanding the clinical utility of PARP inhibitors, reinforcing their role in oncology and potentially other therapeutic areas in the future.

Competition centers in the PARP inhibitor biomarkers sector on identifying and validating predictive biomarkers for targeted therapies in cancer treatment. Key PARP inhibitor biomarkers vendors such as Pfizer, AstraZeneca, and Merck are escalating research, focusing on efficacy and resistance mechanisms. Emerging biotech firms contribute with innovative biomarker discovery platforms, strengthening market dynamics.

The overall PARP inhibitor biomarkers industry is sorted based on product, service, application, end-use, and region.

In the PARP inhibitor biomarkers market, a strong CAGR is predicted for the assay segment over the 2024 to 2032 timeline. These technologies enable more precise identification and characterization of biomarkers associated with PARP inhibitor response, enhancing patient stratification and treatment efficacy. As assays become more sophisticated and accessible, healthcare providers can better tailor therapies based on individual biomarker profiles, optimizing patient outcomes. This trend highlights the growing importance of biomarker-driven approaches in oncology and other therapeutic areas, catapulting the adoption of PARP inhibitor biomarkers as essential tools in clinical practice and drug development.

The HRD testing segment will attain a significant PARP inhibitor biomarkers market share by 2032 because of their role in identifying patients who benefit from PARP inhibitor therapies. HRD testing evaluates genetic abnormalities that affect DNA repair mechanisms, such as BRCA mutations, which can predict response to PARP inhibitors. As these biomarkers gain recognition for their predictive value in treatment selection, healthcare providers are integrating HRD testing into routine oncology practices. This trend reflects a broader shift towards personalized medicine, where biomarker-driven approaches improve treatment precision and patient outcomes in cancer care.

Europe PARP inhibitor biomarkers market will exhibit a robust CAGR from 2024 to 2032. One significant catalyst is the robust healthcare infrastructure and emphasis on advancing precision medicine. European healthcare systems are increasingly adopting biomarker-driven approaches to cancer treatment, enhancing patient outcomes and cost-effectiveness. According to the European Cancer Information System ECIS, as of April 2022, 21% of breast cancer cases in Europe occur in women under 50, the peak incidence age group. Another 35% are diagnosed in women aged 50-64, with the rest in those aged 65 and older.

Regulatory bodies in Europe have been supportive of innovative therapies and biomarker-based diagnostics, facilitating faster adoption and integration into clinical practice. As awareness of PARP inhibitors efficacy in treating cancers with specific biomarkers grows, so does their utilization in European oncology centers, underscoring their pivotal role in modern cancer care strategies.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of breast cancer
    • 3.2.1.2 Advancements in genomic technologies
    • 3.2.1.3 Rising expenditure for cancer treatment
    • 3.2.1.4 Growing adoption of personalized medicine and precision therapy
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of PARP inhibitor biomarker test kits and assays
    • 3.2.2.2 Limited awareness and understanding of PARP inhibitors biomarkers
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Kits
• 5.3 Assays

Chapter 6 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 BRCA (Breast cancer gene) 1 & 2 testing
• 6.3 HRD (Homologous recombination deficiency) testing
• 6.4 HRR (Homologous recombination repair) testing
• 6.5 Other services

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Breast cancer
• 7.3 Ovarian cancer
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Diagnostic laboratories
• 8.4 Academic and research institutes
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Agilent Technologies, Inc.
• 10.2 Ambry Genetics
• 10.3 Amoy Diagnostics Co., Ltd.
• 10.4 Centogene N.V
• 10.5 Illumina, Inc.
• 10.6 Invitae Corporation
• 10.7 Myriad Genetics, Inc.
• 10.8 Neogenomics, Inc.
• 10.9 QIAGEN N.V.
• 10.10 Thermo Fisher Scientific Inc.